AstraZeneca posted higher profit in the first quarter, driven by sales of its diabetes and cancer medicines. The British ...

The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core ...

EWHC ruling discusses application of EPO case law regarding lack of plausibility and lack of technical contribution | Court ...

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

The Russian drugmaker Akrikhin has filed a lawsuit against UK pharma major AstraZeneca (LSE: AZN) to the Moscow Intellectual ...

AstraZeneca's 'smoker's lung' therapy meets ... regulator data shows Popular Western medicines for diseases including cancer and diabetes have been caught in the escalating U.S.-China trade ...

AstraZeneca Plc’s Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage pharmaceuticals and that drugmakers are calling for no additional US levies on ...

To that end, AstraZeneca has scrapped three programs aimed at Alzheimer’s disease, migraine, and pain associated with diabetes or osteoarthritis. The company does still have a Parkinson’s ...